TNFSF9 antibody

Catalog No. ABIN213068

The Rat Monoclonal anti-TNFSF9 antibody has been validated for FACS and IP. It is suitable to detect TNFSF9 in samples from Mouse.

Quick Overview for TNFSF9 antibody (ABIN213068)

Target: TNFSF9 (Tumor Necrosis Factor (Ligand) Superfamily, Member 9 (TNFSF9))

Reactivity: Mouse

Host: Rat

Clonality: Monoclonal

Conjugate: This TNFSF9 antibody is un-conjugated

Application: Flow Cytometry (FACS), Immunoprecipitation (IP)

Product Details anti-TNFSF9 Antibody

Specificity: Recognizes murine 4-1BB Ligand (CD137L), a 50kD type 2 transmembrane protein, which is a member of the TNF superfamily. In mice CD137L is expressed on activated T-cells, B-cells, macrophages and dendritic cells. Interaction of CD137L with its receptor 4-1BB (CD137) is reported to be involved in T and B cell growth and T cell effector function.

Purification: Protein G purified

Immunogen: 41BBL-Fc Fusion Protein.

Type of Immunogen: Fusion protein

Isotype: IgG1

Application Details

Application Notes: Approved: Flo (1:10 - 1:50), IP

Usage: Flow Cytometry: Use 10 μL of the suggested working dilution to label 10^6 cells in 100 μL. Method sheets are available on request.

Comment:

Target Species of Antibody: Mouse

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: Lot specific

Buffer: PBS,  pH 7.4, 0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freezing and thawing.

Storage: 4 °C,-20 °C

Storage Comment: 4°C or -20°C, Avoid freeze-thaw cycles.

Target Details for TNFSF9

Target: TNFSF9 (Tumor Necrosis Factor (Ligand) Superfamily, Member 9 (TNFSF9))

Alternative Name: TNFSF9 / CD137L

Background: Name/Gene ID: TNFSF9
Family: TNF

Synonyms: TNFSF9, 4-1BBL, 4-1BB ligand, 4-1BB-L, CD137L, Homolog of mouse 4-1BB-L, Receptor 4-1BB ligand

Gene ID: 8744

UniProt: P41273

Pathways: Activated T Cell Proliferation, Cancer Immune Checkpoints